Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 50 – No. 7/2012 (500-504)
Antipsychotic treatment in older schizophrenia patients with extrapyramidal side effects in Asia (2001 – 2009)
Yu-Tao Xiang1,2, Julie Kreyenbuhl3,4, Faith B. Dickerson5, Gabor S. Ungvari6, Chuan‑Yue Wang2, Tian-Mei Si7, Edwin H.M. Lee1, Helen F.K. Chiu1, Kelly Y. C. Lai1, Yan-Ling He8, Shu-Yu Yang9, Mian-Yoon Chong10, Chay-Hoon Tan11, Ee‑Heok Kua11, Senta Fujii12, Kang Sim13, Michael K.H. Yong13, Jitendra K. Trivedi14, Eun‑Kee Chung15, Pichet Udomratn16, Kok-Yoon Chee17, Norman Sartorius18 and Naotaka Shinfuku19
1Department of Psychiatry, Chinese University of Hong Kong, Hong Kong SAR, 2Beijing Anding Hospital, Capital Medical University, Beijing, China, 3Division of Services Research, Department of Psychiatry, University of Maryland School of Medicine, 4Veterans Administration Capitol Healthcare Network (VISN 5) Mental Illness Research, Education, and Clinical Center (MIRECC), 5The Stanley Research Program at Sheppard Pratt, Baltimore, MD, USA, 6School of Psychiatry & Clinical Neurosciences, University of Western Australia, Perth, Australia, 7Key Laboratory of Mental Health, Ministry of Mental Health & Peking University Institute of Mental Health, Beijing, 8Shanghai Mental Health Center, Shanghai, China, 9Taipei City Hospital, Taipei, 10Kaohsiung Chang Gung Memorial Hospital and School of Medicine, Chang Gung University, Taiwan, 11National University of Singapore, Singapore, 12Hyogo Institute for Traumatic Stress (HITS), Kobe, Japan, 13Institute of Mental Health, Buangkok View, Singapore, 14Department of Psychiatry, C.S.M.Medical University UP, Lucknow, Uttar Pradesh, India, 15National Seoul Hospital, Seoul, Korea, 16Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, 17Department of Psychiatry and Mental Health, Tunku Abdul Rahman Institute of Neuroscience, Kuala Lumpur Hospital, Malaysia, 18Association for the Improvement of Mental Health Programs, Geneva, Switzerland and 19School of Human Sciences, Seinan Gakuin University Fukuoka, Japan
Kaohsiung Chang Gung Memorial Hospital and School of Medicine, Chang Gung University, Taiwan, National University of Singapore, Singapore, Hyogo Institute for Traumatic Stress (HITS), Kobe, Japan, Institute of Mental Health, Buangkok View,
Singapore, Department of Psychiatry, C.S.M.Medical University UP, Lucknow, Uttar
Pradesh, India, National Seoul Hospital, Seoul, Korea, Department of Psychiatry,
Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, Department of
Psychiatry and Mental Health, Tunku Abdul Rahman Institute of Neuroscience, Kuala Lumpur Hospital, Malaysia, Association for the Improvement of Mental Health Programs, Geneva, Switzerland and School of Human Sciences, Seinan Gakuin University Fukuoka, Japan
Objective: This study surveyed the prescribing patterns of antipsychotic medications in Asian older schizophrenia patients with extrapyramidal side effects (EPS) during the period between 2001 and 2009. Method: Information on 848 hospitalized patients with schizophrenia aged 60 or older was extracted from the database of the Research on Asian Psychotropic Prescription Patterns (REAP) study (2001 – 2009). Data from those patients with reported EPS from 8 Asian countries and territories including China, Hong Kong, Japan, Korea, Singapore, Taiwan, India and Malaysia were analyzed. The cross-sectional data of sociodemographic and clinical characteristics and antipsychotic prescriptions were collected using a standardized protocol and data collection procedure. Results: Of the 309/848 (36%) patients suffering from EPS, 210 patients (210/309; 68.0%) received at least one type of first generation antipsychotic (FGA), and 99 (99/309; 32.0%) received second generation antipsychotics (SGAs) only. Of SGAs prescribed in patients with EPS, risperidone was the most commonly used (100/309; 32.4%) followed by olanzapine (33/309; 10.7%) and quetiapine (25/309; 8.1%). Conclusions: FGAs were frequently used in Asian older schizophrenia patients with EPS. Considering the potential adverse effects of FGAs on existing EPS, the reasons for the frequent use of FGAs need to be urgently identified.Correspondence to:
Dr. Yu-Tao Xiang
Department of Psychiatry
Chinese University of Hong Kong
Ground Floor, Multicentre, Tai Po Hospital
Tai Po, N.T., Hong Kong, China
Email: [email protected]
